Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Kezar Life Sciences, Inc. (KZR) had Return on Tangible Equity of -16.06% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-16.56M |
|
-- |
|
-- |
|
$17.63M |
|
$-17.63M |
|
$1.07M |
|
$-16.56M |
|
$-16.56M |
|
$-16.56M |
|
$-16.56M |
|
$-16.56M |
|
$-16.56M |
|
$-17.63M |
|
$-17.91M |
|
7.31M |
|
7.31M |
|
$-2.27 |
|
$-2.27 |
|
| Balance Sheet Financials | |
$120.32M |
|
$2.65M |
|
$4.94M |
|
$125.26M |
|
$16.96M |
|
$3.87M |
|
$5.23M |
|
$22.19M |
|
$103.07M |
|
$103.07M |
|
$103.07M |
|
7.31M |
|
| Cash Flow Statement Financials | |
$-17.19M |
|
$13.74M |
|
$-1.30M |
|
$41.75M |
|
$37.00M |
|
$-4.75M |
|
$2.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.09 |
|
-- |
|
-- |
|
0.04 |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.06% |
|
|
Return on Tangible Equity |
-16.06% |
-13.22% |
|
-15.48% |
|
$14.11 |
|
$-2.35 |
|
$-2.35 |
|